SNGXSoligenix Inc
SNGX
Soligenix Inc12,772
Mkt Cap
$11.54MVolume
104,060.0052W High
$6.2352W Low
$1.00PE Ratio
-0.41SNGX Fundamentals
Price
$1.12Prev Close
$1.14Open
$1.1550D MA
$1.16Beta
0.58Avg. Volume
320,086.08EPS (Annual)
-$2.14P/B
2.13Rev/Employee
$0.00$0.625
Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy Positive Clinical Results...
PR Newswire·10d ago
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide […]
Investor Brand Network·10d ago
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results PR Newswire PRINCETON, N.J., March 31, 2026 Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2...
PR Newswire·12d ago
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behet's Disease
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behet's Disease Soligenix Receives Orphan Drug Designation from the European Commission for...
PR Newswire·17d ago
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026...
PR Newswire·20d ago
Soligenix Announces HyBryte Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix Announces HyBryte Clinical Summary Published in 'Expert Opinion on Investigational Drugs' Soligenix Announces HyBryte Clinical Summary Published in 'Expert Opinion on Investigational Drugs...
PR Newswire·24d ago
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency Soligenix Announces SGX945 Receives Promising Innovative...
PR Newswire·1mo ago
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease Soligenix Receives Positive Opinion...
PR Newswire·1mo ago
Soligenix to Present at BIO Investment & Growth Summit
Soligenix to Present at BIO Investment & Growth Summit Soligenix to Present at BIO Investment & Growth Summit PR Newswire PRINCETON, N.J., Feb. 24, 2026 PRINCETON, N.J., Feb. 24, 2026 /PRNewswire...
PR Newswire·2mo ago
Soligenix Details Recent Progress and Upcoming Milestones
Soligenix Details Recent Progress and Upcoming Milestones Soligenix Details Recent Progress and Upcoming Milestones PR Newswire PRINCETON, N.J., Feb. 12, 2026 PRINCETON, N.J., Feb. 12, 2026...
PR Newswire·2mo ago
<
1
2
...
>